Home › Funds › Casdin Capital › NGNE
Casdin Capital position in NGNE
NEUROGENE INC · Health Care
Casdin Capital reported holding 1,585,361 shares of NGNE (NEUROGENE INC) in its Q3 2026 13F filing — a position valued at US$44.1M, representing 1.93% of its reported portfolio and ranking #9 among its reported holdings. Casdin Capital has disclosed NGNE holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Casdin Capital's NGNE position evolved
Casdin Capital first disclosed a stake in NGNE in Q4 2023 at 524,616 shares (US$10.2M). The position peaked in Q2 2026 at 1,545,361 shares, worth US$48.6M. Across 12 filings, Casdin Capital increased the stake 4 time(s), trimmed it 0 time(s) and left it unchanged 7 time(s). The most recent filing (Q3 2026) shows 1,585,361 shares valued at US$44.1M — an increase of 40,000 shares quarter over quarter.. Notable position changes include a 147% increase in Q4 2024 (shares fell 49% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 524.62K | $10.17M | New |
| Q1 2024 | 524.62K | $26.70M | Hold |
| Q2 2024 | 524.62K | $19.09M | Hold |
| Q3 2024 | 524.62K | $22.01M | Hold |
| Q4 2024 | 1.30M | $29.61M | Add |
| Q1 2025 | 1.30M | $15.17M | Hold |
| Q2 2025 | 1.30M | $19.37M | Hold |
| Q3 2025 | 1.30M | $22.45M | Hold |
| Q4 2025 | 1.30M | $26.68M | Hold |
| Q1 2026 | 1.42M | $28.63M | Add |
| Q2 2026 | 1.55M | $48.60M | Add |
| Q3 2026 | 1.59M | $44.10M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NGNE and 13F data
NGNE (NEUROGENE INC) is a Health Care company. 41 other funds we track also report a position in NGNE — the largest reported positions include Samsara BioCapital, LLC (US$51.9M), Redmile Group, LLC (US$43.5M), RTW INVESTMENTS, LP (US$42.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NGNE
- Samsara BioCapital, LLC 1.87M sh · $51.94M · Q3 2026
- Redmile Group, LLC 1.56M sh · $43.46M · Q3 2026
- RTW INVESTMENTS, LP 1.51M sh · $42.08M · Q3 2026
- EcoR1 Capital, LLC 1.27M sh · $35.37M · Q3 2026
- BAKER BROS. ADVISORS LP 991.69K sh · $27.59M · Q3 2026
- Trails Edge Capital Partners, LP 964.88K sh · $26.84M · Q3 2026
- MPM BioImpact LLC 771.84K sh · $21.47M · Q3 2026
- Tyro Capital Management LLC 304.40K sh · $8.47M · Q3 2026
- GREAT POINT PARTNERS LLC 300.00K sh · $8.35M · Q3 2026
- Jones Hill Capital LP 217.70K sh · $6.06M · Q3 2026
- DAFNA Capital Management LLC 150.53K sh · $4.19M · Q3 2026
More on Casdin Capital
FAQ
How long has Casdin Capital held NGNE?
Casdin Capital has disclosed NGNE holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
What is Casdin Capital's current position in NGNE?
As of Q3 2026, Casdin Capital holds 1.59M shares of NGNE (NEUROGENE INC), valued at $44.10M, representing 1.93% of its reported portfolio and ranking #9.
Has Casdin Capital been buying or selling NGNE?
In the latest 13F filing (Q3 2026), Casdin Capital increased its position in NGNE. The position peaked in Q2 2026 at 1.55M shares.
Which other funds hold NGNE?
Other major institutional holders of NGNE include Samsara BioCapital, LLC, Redmile Group, LLC, RTW INVESTMENTS, LP, among 41 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.